OTTAWA, Ontario, June 24, 2025 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and strategic growth critical infrastructure sectors, today announced that Chris Pogue will join the company as President, Defence & Space, effective July 7, 2025. In this newly created role, Pogue will lead a high-performance organization that brings together Calian’s Advanced Technologies and Learning business units—leveraging the synergies of its comm ...

文章核心观点 公司增强TrustMANAGER平台以应对物联网安全挑战并支持法规合规，该平台可解决物联网安全、法规遵从等关键问题，适用于物联网设备制造商和工业自动化提供商 [1][4] 行业动态 - 国际网络安全法规不断适应威胁演变，重点关注物联网设备过时固件带来的安全漏洞 [1] - 欧洲网络弹性法案（CRA）对欧盟销售的数字产品强制要求强网络安全措施，预计影响全球法规 [1] - 无线电设备指令（RED）为欧盟无线电设备制定严格标准，自2025年8月1日起，欧盟市场销售的无线设备须遵守其网络安全规定 [3] 公司举措 - 增强TrustMANAGER平台，增加安全代码签名、固件空中下载（FOTA）更新交付以及固件映像、加密密钥和数字证书的远程管理功能 [1] - ECC608 TrustMANAGER利用Kudelski IoT的keySTREAM™ SaaS提供安全认证集成电路，添加FOTA服务后可帮助客户安全部署实时固件更新 [2] - Microchip WINCS02PC Wi - Fi网络控制器模块获RED认证，实现安全可靠的云连接 [3] 产品优势 - FOTA服务为客户提供可扩展解决方案，节省资源，满足合规要求，使产品适应新兴威胁和法规变化 [3] - TrustMANAGER解决物联网安全、法规合规、设备生命周期管理和车队管理等关键挑战 [4] 开发工具 - ECC608 TrustMANAGER与MPLAB X集成开发环境兼容，由CryptoAuth PRO开发板和CryptoAuthLib软件库支持 [5] - 信任平台设计套件（TPDS）包含用例示例、教育步骤和固件代码示例，可启用keySTREAM服务 [5] 购买信息 - 可直接从Microchip购买，或联系销售代表或全球授权经销商 [6] 资源信息 - 可通过Flickr获取高分辨率应用图像 [7] - 可下载Microchip的CRA白皮书 [7] - 可访问信任平台设计套件相关网站 [8] 公司介绍 - 是智能、连接和安全嵌入式控制与处理解决方案的领先提供商，工具易用、产品组合全面 [9] - 解决方案服务超100,000家客户，涵盖多个市场，总部位于亚利桑那州钱德勒 [9]

TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB) ("RWB" or the "Company") announces that its Annual General Meeting ("AGM"), originally scheduled for Friday, June 27, 2025, has been rescheduled to Friday, July 11, 2025. The change will allow for the completion and filing of the Company's audited financial statements and accompanying management discussion and analysis for the year-ended December 31, 2024, both of which will be presented at the AGM. The change to the annual ...

TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- STORAGEVAULT CANADA INC. ("StorageVault") (SVI-TSX) is pleased to announce that, further to its April 23, 2025 news release, it has completed the acquisition of seven stores and one adjacent vacant parcel of land (collectively, the "Acquisitions") from six vendor groups (collectively, the "Vendors"), for an aggregate purchase price of $71.9 million. Six of the Acquisitions are arm's length and two, totaling $21.9 million, are related party acquisitions (the "Relate ...

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, ...

IRVINE, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced that Lantronix has been named the 2025 Industrial IoT Company of the Year by CompassIntel, a leading market research and advisory firm specializing in metrics-driven market intelligence and insights for the mobile, IoT and high-tech industries. The 13 annual CompassIntel Awards honor companies, vendors and organizations ...

文章核心观点 公司与Recordati达成独家长期许可和供应协议，将VAZKEPA在欧洲59个国家商业化，借此精简全球运营，预计未来12个月节省约7000万美元成本，加速实现正现金流，强化财务状况和战略地位，为股东创造价值 [1][2] 欧洲许可协议 - Recordati是国际制药公司，总部位于意大利米兰，业务覆盖研发、生产、商业化和许可，心血管疾病业务约占其专科和初级保健业务的25%，业务遍布超150个国家 [3] - Recordati负责VAZKEPA在欧洲的商业化，公司将获2500万美元预付款和最高达1.5亿美元的里程碑付款，还有供应相关收入 [5] 公司增长战略 - 与Recordati合作使公司更好利用VASCEPA/VAZKEPA全球潜力，提高运营效率，从多渠道获取收入，强化财务状况，加速实现正现金流 [6] - 公司立即进行全球重组，大部分成本节省来自欧洲业务商业化费用减少，预计未来12个月节省约7000万美元成本 [12] - 继续最大化美国业务，美国业务成熟且盈利，有多种方式推动VASCEPA收入和现金流增长 [12] - 通过与加拿大、中东和北非、中国、澳大利亚/新西兰和东南亚等国际市场的合作伙伴关系高效创收，支持合作伙伴监管和商业工作，最大化产品全球价值 [12] 产品信息 - VASCEPA是首个获美国FDA批准、仅含活性成分二十碳五烯酸乙酯（IPE）的处方治疗药物，2020年1月在美国上市，用于治疗有持续心血管风险的高危患者，上市后处方超2500万次，多数主要医疗保险计划可报销 [11][13] - VAZKEPA于2021年3月在欧盟、4月在英国获批用于降低高心血管风险患者心血管事件风险，目前在欧洲多个国家获批销售 [13] 会议与材料信息 - 公司将于美国东部时间上午8点举行电话会议讨论该协议，可通过公司网站或电话接入，会议结束后两周内可收听回放 [8] - 投资者材料可在AdvancingAmarin.com获取 [9] 公司与产品介绍 - 公司是创新制药公司，致力于心血管疾病管理，在美国、爱尔兰、瑞士等地设有办公室，在全球有商业合作伙伴和供应商 [10] - VASCEPA在美国用于降低心肌梗死、中风等风险及降低严重高甘油三酯血症患者甘油三酯水平，对胰腺炎风险影响未确定，对鱼和/或贝类过敏患者使用时需注意 [14][19] - 欧洲VAZKEPA产品特性总结信息可访问指定链接，全球处方信息有差异，需参考各国产品标签 [17] 其他信息 - 巴克莱担任此次交易财务顾问，公司董事会和管理层将继续探索战略行动以实现股东价值最大化 [7] - Wilke Farr & Gallagher LLP担任协议法律顾问 [7] - 公司通过官网和投资者关系网站等渠道与投资者和公众沟通，鼓励相关方定期查看信息 [21] - 提供投资者和媒体咨询联系方式 [22]

Dublin, Ireland, June 24, 2025 (GLOBE NEWSWIRE) -- Brera Holdings PLC ("Brera Holdings" or the "Company") (Nasdaq: BREA), an Ireland-based international holding company focused on expanding its global portfolio of men's and women's sports clubs through a multi-club ownership ("MCO") strategy, today announced a 1-for-10 reverse share split (the "Reverse Share Split") of the Company's ordinary shares, wherein the 50,000,000 Class A Ordinary Shares of nominal value $0.005 each will be consolidated on a 1-for-1 ...

SmartGateway Deployment Addresses California’s New Mandate for Hospital Weapons DetectionTORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its SmartGateway has been selected by San Mateo Medical Center, located in San Mateo, CA, to strengthen the facility’s security and provide AI-powered weapon detection. Xtract One’s leading technology-driven threat detection and security solutions are designed to enhance ...

Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer- acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: ...